Format
Sort by

Send to:

Choose Destination

Results: 3

1.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

Crit Care Med. 2004 Nov;32(11):2199-206.

PMID:
15640631
2.

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.

PMID:
12544987
3.

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):1-11.

PMID:
12544986
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk